Tumor angiogenesis at baseline identified by 18F-Alfatide II PET/CT may predict survival among patients with locally advanced non-small cell lung cancer treated with concurrent chemoradiotherapy

Tumor angiogenesis at baseline identified by 18F-Alfatide II PET/CT may predict survival among patients with locally advanced non-small cell lung cancer treated with concurrent chemoradiotherapy

Abstract Background The study investigated the predictive value of tumor angiogenesis observed by 18F-ALF-NOTA-PRGD2 II (denoted as 18F-Alfatide II) positron emission tomography (PET)/computed tomography (CT) before concurrent chemoradiotherapy (CCRT) for treatment response and survival among patien...

Full description

Bibliographic Details
Main Authors: Yuchun Wei, Xueting Qin, Xiaoli Liu, Jinsong Zheng, Xiaohui Luan, Yue Zhou, Jinming Yu, Shuanghu Yuan
Format: Article
Language:English
Published: BMC 2022-02-01
Series:Journal of Translational Medicine
Subjects:
18F-alfatide
PET/CT
Non-small cell lung cancer
Chemoradiotherapy
Online Access:https://doi.org/10.1186/s12967-022-03256-3

Internet

https://doi.org/10.1186/s12967-022-03256-3

Similar Items